Shortages of testing supplies may hinder COVID-19 testing. After issues with faulty tests and not enough tests, labs are facing a severe shortage of testing supplies like chemical components and swabs to collect samples. (Associated Press)

Coronavirus is affecting drug studies. The Apple Watch and Johnson & Johnson heart study announced earlier this year is just one example. But this study, which collects information virtually, may also be a blueprint for future virtual trials. (STAT)

How countries around the world are responding to the coronavirus. Different approaches have led to more or less spread in every country. Some, like Singapore, took early steps and have seen lower case counts. (STAT)

Novartis will donate doses of malaria drug hydroxychloroquine to treat COVID-19 patients. The company said, if approved, it will donate enough medicine to treat several million patients. A trial is currently studying hydroxychloroquine as a COVID-19 treatment. (Reuters)

Other drugmakers like Teva and Mylan are ramping up production of the malaria drug. Teva said it would donate 6 million tablets of the drug to hospitals by the end of the month. Mylan is restarting manufacturing at a West Virginia plant. (BioPharma Dive)